IL-7 signaling imparts polyfunctionality and stemness potential to CD4+ T cells

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Ding, Zhi Chun ^a   Liu, Chufeng ^a,b   Cao, Yang ^a,c   Habtetsion, Tsadik ^a   Kuczma, Michal ^a   Pi, Wenhu ^a   Kong, Heng ^a,d   Cacan, Ercan ^e   Greer, Susanna F ^e   Cui, Yan ^a   Blazar, Bruce R ^f   Munn, David H ^a   Zhou, Gang ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

^e GEORGIA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adoptive cell therapy; CD4+; IL 7; polyfunctional; T memory stem cell

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GRANZYME B; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; L SELECTIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTONE ACETYLATION; HOMEOSTASIS; IMMUNIZATION; MOUSE; NONHUMAN; POLYFUNCTIONALITY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REJECTION;

EID: 84976286543     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1171445     Document Type: Article

References (59)

1. K.Hung, R.Hayashi, A.Lafond-Walker, C.Lowenstein, D.Pardoll, H.Levitsky. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68; PMID:9858522; 10.1084/jem.188.12.2357
2. M.E.Dudley, J.R.Wunderlich, P.F.Robbins, J.C.Yang, P.Hwu, D.J.Schwartzentruber, S.L.Topalian, R.Sherry, N.P.Restifo, A.M.Hubicki et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; 10.1126/science.1076514
3. A.L.Marzo, B.F.Kinnear, R.A.Lake, J.J.Frelinger, E.J.Collins, B.W.Robinson, B.Scott. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047-55; PMID:11086036; 10.4049/jimmunol.165.11.6047
4. F.Ossendorp, E.Mengede, M.Camps, R.Filius, C.J.Melief. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187:693-702; PMID:9480979; 10.1084/jem.187.5.693
5. A.Schietinger, M.Philip, R.B.Liu, K.Schreiber, H.Schreiber. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010; 207:2469-77; PMID:20921286; 10.1084/jem.20092450
6. A.Perez-Diez, N.T.Joncker, K.Choi, W.F.Chan, C.C.Anderson, O.Lantz, P.Matzinger. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; 10.1182/blood-2006-10-051318
7. A.Corthay, D.K.Skovseth, K.U.Lundin, E.Rosjo, H.Omholt, P.O.Hofgaard, G.Haraldsen, B.Bogen. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371-83; PMID:15780993; 10.1016/j.immuni.2005.02.003
8. S.A.Quezada, T.R.Simpson, K.S.Peggs, T.Merghoub, J.Vider, X.Fan, R.Blasberg, H.Yagita, P.Muranski, P.A.Antony et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; 10.1084/jem.20091918
9. H.Z.Qui, A.T.Hagymasi, S.Bandyopadhyay, M.C.St Rose, R.Ramanarasimhaiah, A.Menoret, R.S.Mittler, S.M.Gordon, S.L.Reiner, A.T.Vella et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011; 187:3555-64; PMID:21880986; 10.4049/jimmunol.1101244
10. Y.Xie, A.Akpinarli, C.Maris, E.L.Hipkiss, M.Lane, E.K.Kwon, P.Muranski, N.P.Restifo, P.A.Antony. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67; PMID:20156973; 10.1084/jem.20091921
11. N.N.Hunder, H.Wallen, J.Cao, D.W.Hendricks, J.Z.Reilly, R.Rodmyre, A.Jungbluth, S.Gnjatic, J.A.Thompson, C.Yee. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; 10.1056/NEJMoa0800251
12. E.Tran, S.Turcotte, A.Gros, P.F.Robbins, Y.C.Lu, M.E.Dudley, J.R.Wunderlich, R.P.Somerville, K.Hogan, C.S.Hinrichs et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; 10.1126/science.1251102
13. J.P.Casazza, M.R.Betts, D.A.Price, M.L.Precopio, L.E.Ruff, J.M.Brenchley, B.J.Hill, M.Roederer, D.C.Douek, R.A.Koup. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203:2865-77; PMID:17158960; 10.1084/jem.20052246
14. P.A.Darrah, D.T.Patel, P.M.De Luca, R.W.Lindsay, D.F.Davey, B.J.Flynn, S.T.Hoff, P.Andersen, S.G.Reed, S.L.Morris et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50; PMID:17558415; 10.1038/nm1592
15. M.L.Precopio, M.R.Betts, J.Parrino, D.A.Price, E.Gostick, D.R.Ambrozak, T.E.Asher, D.C.Douek, A.Harari, G.Pantaleo et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204:1405-16; PMID:17535971; 10.1084/jem.20062363
16. D.M.Brown, S.Lee, L.Garcia-Hernandez Mde, S.L.Swain. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol 2012; 86:6792-803; PMID:22491469; 10.1128/JVI.07172-11
17. Z.C.Ding, B.R.Blazar, A.L.Mellor, D.H.Munn, G.Zhou. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010; 115:2397-406; PMID:20118405; 10.1182/blood-2009-11-253336
18. Z.C.Ding, L.Huang, B.R.Blazar, H.Yagita, A.L.Mellor, D.H.Munn, G.Zhou. Polyfunctional CD4(+) T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012; 120:2229-39; PMID:22859605; 10.1182/blood-2011-12-398321
19. D.Hirschhorn-Cymerman, S.Budhu, S.Kitano, C.Liu, F.Zhao, H.Zhong, A.M.Lesokhin, F.Avogadri-Connors, J.Yuan, Y.Li et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 2012; 209:2113-26; PMID:23008334; 10.1084/jem.20120532
20. M.Ayyoub, D.Dojcinovic, P.Pignon, I.Raimbaud, J.Schmidt, I.Luescher, D.Valmori. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci USA 2010; 107:7437-42; PMID:20368442; 10.1073/pnas.1001322107
21. Y.Lin, H.F.Gallardo, G.Y.Ku, H.Li, G.Manukian, T.S.Rasalan, Y.Xu, S.L.Terzulli, L.J.Old, J.P.Allison et al. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009; 11:912-22; PMID:19903103; 10.3109/14653240903136987
22. J.Yuan, S.Gnjatic, H.Li, S.Powel, H.F.Gallardo, E.Ritter, G.Y.Ku, A.A.Jungbluth, N.H.Segal, T.S.Rasalan et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105:20410-5; PMID:19074257; 10.1073/pnas.0810114105
23. T.J.Fry, C.L.Mackall. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6; PMID:15905493; 10.4049/jimmunol.174.11.6571
24. L.M.Bradley, L.Haynes, S.L.Swain. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005; 26:172-6; PMID:15745860; 10.1016/j.it.2005.01.004
25. H.Hock, M.Dorsch, T.Diamantstein, T.Blankenstein. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174:1291-8; PMID:1683890; 10.1084/jem.174.6.1291
26. T.Aoki, K.Tashiro, S.Miyatake, T.Kinashi, T.Nakano, Y.Oda, H.Kikuchi, T.Honjo. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992; 89:3850-4; PMID:1570303; 10.1073/pnas.89.9.3850
27. S.A.Rosenberg, C.Sportes, M.Ahmadzadeh, T.J.Fry, L.T.Ngo, S.L.Schwarz, M.Stetler-Stevenson, K.E.Morton, S.A.Mavroukakis, M.Morre et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; PMID:16699374; 10.1097/01.cji.0000210386.55951.c2
28. C.Sportes, R.R.Babb, M.C.Krumlauf, F.T.Hakim, S.M.Steinberg, C.K.Chow, M.R.Brown, T.A.Fleisher, P.Noel, I.Maric et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16:727-35; PMID:20068111; 10.1158/1078-0432.CCR-09-1303
29. C.Sportes, F.T.Hakim, S.A.Memon, H.Zhang, K.S.Chua, M.R.Brown, T.A.Fleisher, M.C.Krumlauf, R.R.Babb, C.K.Chow et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-14; PMID:18573906; 10.1084/jem.20071681
30. M.A.Cheever. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; 10.1111/j.1600-065X.2008.00604.x
31. C.L.Mackall, T.J.Fry, R.E.Gress. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-42; PMID:21508983; 10.1038/nri2970
32. M.Kalos, C.H.June. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; 10.1016/j.immuni.2013.07.002
33. C.A.Klebanoff, H.T.Khong, P.A.Antony, D.C.Palmer, N.P.Restifo. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26:111-7; PMID:15668127; 10.1016/j.it.2004.12.003
34. E.Zhao, T.Maj, I.Kryczek, W.Li, K.Wu, L.Zhao, S.Wei, J.Crespo, S.Wan, L.Vatan et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016; 17:95-103; PMID:26523864; 10.1038/ni.3313
35. N.van Panhuys, F.Klauschen, R.N.Germain. T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization in vivo. Immunity 2014; 41:63-74; PMID:24981853; 10.1016/j.immuni.2014.06.003
36. Y.L.Chiu, L.Shan, H.Huang, C.Haupt, C.Bessell, D.H.Canaday, H.Zhang, Y.C.Ho, J.D.Powell, M.Oelke et al. Sprouty-2 regulates HIV-specific T cell polyfunctionality. J Clin Invest 2014; 124:198-208; PMID:24292711; 10.1172/JCI70510
37. M.S.Schlissel, S.D.Durum, K.Muegge. The interleukin 7 receptor is required for T cell receptor gamma locus accessibility to the V(D)J recombinase. J Exp Med 2000; 191:1045-50; PMID:10727465; 10.1084/jem.191.6.1045
38. M.L.Stanton, P.H.Brodeur. Stat5 mediates the IL-7-induced accessibility of a representative D-Distal VH gene. J Immunol 2005; 174:3164-8; PMID:15749844; 10.4049/jimmunol.174.6.3164
39. S.K.Ye, Y.Agata, H.C.Lee, H.Kurooka, T.Kitamura, A.Shimizu, T.Honjo, K.Ikuta. The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. Immunity 2001; 15:813-23; PMID:11728342; 10.1016/S1074-7613(01)00230-8
40. Y.Rochman, R.Spolski, W.J.Leonard. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480-90; PMID:19543225; 10.1038/nri2580
41. L.Gattinoni, C.A.Klebanoff, N.P.Restifo. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671-84; PMID:22996603; 10.1038/nrc3322
42. A.Boyd, J.R.Almeida, P.A.Darrah, D.Sauce, R.A.Seder, V.Appay, G.Gorochov, M.Larsen. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection. PLoS One 2015; 10:e0128714; PMID:26046523; 10.1371/journal.pone.0128714
43. E.Cha, L.Graham, M.H.Manjili, H.D.Bear. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat 2010; 122:359-69; PMID:19826947; 10.1007/s10549-009-0573-0
44. S.Caserta, P.Alessi, V.Basso, A.Mondino. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells. Eur J Immunol 2010; 40:470-9; PMID:19950184; 10.1002/eji.200939801
45. W.J.Murphy, T.C.Back, K.C.Conlon, K.L.Komschlies, J.R.Ortaldo, T.J.Sayers, R.H.Wiltrout, D.L.Longo. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest 1993; 92:1918-24; PMID:8408644; 10.1172/JCI116785
46. J.C.Castle, M.Loewer, S.Boegel, J.de Graaf, C.Bender, A.D.Tadmor, V.Boisguerin, T.Bukur, P.Sorn, C.Paret et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 2014; 15:190; PMID:24621249; 10.1186/1471-2164-15-190
47. H.Braumuller, T.Wieder, E.Brenner, S.Assmann, M.Hahn, M.Alkhaled, K.Schilbach, F.Essmann, M.Kneilling, C.Griessinger et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; 10.1038/nature11824
48. Y.Zhang, G.Joe, E.Hexner, J.Zhu, S.G.Emerson. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 2005; 11:1299-305; PMID:16288282; 10.1038/nm1326
49. L.Gattinoni, E.Lugli, Y.Ji, Z.Pos, C.M.Paulos, M.F.Quigley, J.R.Almeida, E.Gostick, Z.Yu, C.Carpenito et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; 10.1038/nm.2446
50. N.Cieri, B.Camisa, F.Cocchiarella, M.Forcato, G.Oliveira, E.Provasi, A.Bondanza, C.Bordignon, J.Peccatori, F.Ciceri et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573-84; PMID:23160470; 10.1182/blood-2012-05-431718
51. S.Wei, E.Zhao, I.Kryczek, W.Zou. Th17 cells have stem cell-like features and promote long-term immunity. Oncoimmunology 2012; 1:516-9; PMID:22754771; 10.4161/onci.19440
52. P.Muranski, Z.A.Borman, S.P.Kerkar, C.A.Klebanoff, Y.Ji, L.Sanchez-Perez, M.Sukumar, R.N.Reger, Z.Yu, S.J.Kern et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35:972-85; PMID:22177921; 10.1016/j.immuni.2011.09.019
53. L.Zitvogel, L.Apetoh, F.Ghiringhelli, G.Kroemer. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; 10.1038/nri2216
54. Z.C.Ding, G.Zhou. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012:890178; PMID:22400040; 10.1155/2012/890178
55. Z.C.Ding, X.Lu, M.Yu, H.Lemos, L.Huang, P.Chandler, K.Liu, M.Walters, A.Krasinski, M.Mack et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res 2014; 74:3441-53; PMID:24780756; 10.1158/0008-5472.CAN-13-3596
56. S.K.Perna, D.Pagliara, A.Mahendravada, H.Liu, M.K.Brenner, B.Savoldo, G.Dotti. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 2014; 20:131-9; PMID:24097874; 10.1158/1078-0432.CCR-13-1016
57. T.W.Hand, W.Cui, Y.W.Jung, E.Sefik, N.S.Joshi, A.Chandele, Y.Liu, S.M.Kaech. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci USA 2010; 107:16601-6; PMID:20823247; 10.1073/pnas.1003457107
58. M.Onishi, T.Nosaka, K.Misawa, A.L.Mui, D.Gorman, M.McMahon, A.Miyajima, T.Kitamura. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18:3871-9; PMID:9632771; 10.1128/MCB.18.7.3871
59. X.Lu, Z.Ding, Y.Cao, C.Liu, T.Habtetsion, M.Yu, H.Lemos, H.Salman, H.Xu, A.L.Mellor et al. Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol 2015; 194(4):2011-21